Please login to the form below

Not currently logged in
Email:
Password:

Valeant lead bidder for troubled Dendreon

Willing to pay $296m for company behind prostate cancer vaccine Provenge
Dendreon Provenge sipuleucel-T for 
prostate cancer

Ambitious Canadian pharma company Valeant has emerged as the lead bidder for the troubled company Dendreon and its ailing cancer vaccine Provenge.

Valeant has made an initial bid of $296m in cash for Seattle-based Dendreon, which filed for bankruptcy at the end of 2014 as sales of its lead product Provenge (sipuleucel-T) for prostate cancer fell short of expectations.

The bid comes a month after Dendreon first went to auction with a minimum price of $275m but with no initial 'stalking horse' bidder.

This place has now been taken by Valeant, which has built its business the past few years with a series of targeted global acquisitions, including a $2.6bn to takeover dermatology firm Medicis.

Valeant's main interest in 2014 was Botox manufacturer Allergan. However, Allergan resisted Valeant's advances for several months and eventually ended them in November last year after agreeing a $66bn deal with Actavis.

The Dendreon bid puts Valeant back on the acquisition trail, although it could be seen as a risky deal considering the inability of Provenge to gain a sure foothold in the prostate cancer market due in part to its high price, complex treatment process and competition from cheaper conventional drugs such as Johnson & Johnson's Zytiga (abiraterone) and Astellas/Medivation's Xtandi (enzalutamide).

Provenge's uneasy path was compounded last month when the UK cost-effectiveness watchdog NICE deemed the drug too expensive for use on the NHS in England and Wales.

Despite these concerns Valeant sees potential in the product, which was one of the first cancer immunotherapies to hit market when it was approved in 2010 and now sees itself as part of a rapidly growing class of therapy.

J Michael Pearson, chairman and CEO of Valeant said: “We believe that oncology has similar characteristics to our current therapeutic portfolios, such as strong growth, high durability, strong patient and physician loyalty, and a terrific reimbursement regime.

He added: “We have not previously found an economic way to enter this market, but with the unique dynamics of this situation, we believe that this transaction will create significant shareholder value."

Valeant's role as a stalking horse bidder, and the sale itself, are subject to approval by the bankruptcy court. Completion of the transaction remains subject to higher or better offers for Dendreon.

 

2nd February 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...